The B-Cell Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
B-Cell Non-Hodgkin Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of B-Cell Non-Hodgkin Lymphoma and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the B-Cell Non-Hodgkin Lymphoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Learn How the Ongoing Clinical & Commercial Activities will Affect the B-Cell Non-Hodgkin Lymphoma Therapeutic Segment @
B-Cell Non-Hodgkin Lymphoma Therapeutics Landscape
The dynamics of the B-cell NHL market are anticipated to change in the coming years, owing to the launch of emerging therapies. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with B-cell NHL.
Latest Development in the B-Cell Non-Hodgkin Lymphoma Therapeutics Landscape
On April 26, 2023, Artiva Biotherapeutics, Inc., announced that a poster describing initial data from the Phase 1/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell being investigated in combination with rituximab for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
The Leading Players in the B-Cell Non-Hodgkin Lymphoma Therapeutics Market Include:
Takeda Pharma, AstraZeneca, Bayer AG, Novartis, Kite Pharma, Spectrum Pharma, Teva Pharma, Bristol Myers Squibb Company, Janssen Pharma, Genetech Inc., Merck & Co., Sanofi, Abbvie, Kyowa Kirin co. Ltd., and Many Others.
B-Cell Non-Hodgkin Lymphoma Therapies Covered in the Report Include:
AB-101, AB-202: Artiva Biotherapeutics
Abexinostat: Xynomic Pharmaceuticals
CT032 CAR-CD19 T: Carsgen Therapeutics
GB226: Genor Biopharma
Kymriah (tisagenlecleucel): Novartis
Keytruda (Pembrolizumab): Merck Sharp & Dohme
Yescarta (Axicabtagene ciloleucel; KTE-C19): Gilead Sciences
Revlimid (lenalidomide): Celgene Corporation
Velcade (bortezomib): Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical
Zevalin (ibritumomab tiuxetan): Spectrum Pharmaceuticals
Lisocabtagene maraleucel (JCAR017): Bristol-Myers Squibb
Umbralisib (TG-1202): TG Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. B-Cell Non-Hodgkin Lymphoma Current Treatment Patterns
4. B-Cell Non-Hodgkin Lymphoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. B-Cell Non-Hodgkin Lymphoma Late Stage Products (Phase-III)
7. B-Cell Non-Hodgkin Lymphoma Mid-Stage Products (Phase-II)
8. B-Cell Non-Hodgkin Lymphoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. B-Cell Non-Hodgkin Lymphoma Discontinued Products
13. B-Cell Non-Hodgkin Lymphoma Product Profiles
14. Key Companies in the B-Cell Non-Hodgkin Lymphoma Market
15. Key Products in the B-Cell Non-Hodgkin Lymphoma Therapeutics Segment
16. Dormant and Discontinued Products
17. B-Cell Non-Hodgkin Lymphoma Unmet Needs
18. B-Cell Non-Hodgkin Lymphoma Future Perspectives
19. B-Cell Non-Hodgkin Lymphoma Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States